What Is Cardiometabolic HFpEF and How Can We Study it Preclinically?

Area of Science:

• Cardiology
• Metabolic Disease Research
• Translational Medicine

Background:

• Cardiometabolic heart failure with preserved ejection fraction (HFpEF) is a significant and increasing subtype of HFpEF.
• Its rise is linked to the global obesity and metabolic disease pandemic, driven by common comorbidities.
• Current therapeutic strategies for HFpEF have shown limited success, highlighting the need for new approaches.

Purpose of the Study:

• To define the distinct clinical and molecular characteristics of cardiometabolic HFpEF.
• To review existing animal models relevant to cardiometabolic HFpEF.
• To discuss the development of novel animal models for studying this condition.

Main Methods:

• Review of clinical and molecular features defining cardiometabolic HFpEF.
• Evaluation of current animal models for their relevance to cardiometabolic HFpEF.
• Discussion of methodologies for creating new, clinically informative animal models.

Main Results:

• Cardiometabolic HFpEF is characterized by specific clinical presentations and molecular pathways linked to metabolic dysfunction.
• Existing animal models offer insights but may not fully recapitulate the complexity of human cardiometabolic HFpEF.
• There is a need for refined and novel animal models to better understand disease mechanisms.

Conclusions:

• Recognizing cardiometabolic HFpEF as a distinct endotype is crucial for targeted therapeutic development.
• Clinically relevant animal models are essential tools for uncovering molecular underpinnings and advancing treatment strategies.
• Further development and validation of animal models will accelerate progress in managing cardiometabolic HFpEF.